Sanatio BioScience is a platform-based company built on our innovative modular therapeutics design to target and de-activate viruses or rogue cell products in cancers. Our proprietary patent-pending modular system uses biologic components in tandem arrays that focus targeting to specific cell-types and tissues and then, enhance the natural anti-viral activities within cells. Focused targeting of anti-viral activity stops the life cycle of the virus and prevents replication preferentially in infected cells and tissues.
The modular system allows us to rapidly adapt our design to target viruses (current and future). Near term focus on COVID with secondary on next threats/strains such as MERS, SARS, and Influenza by targeting the appropriate virus-specific product in infected cells and tissues. The modular approach gives Sanatio diverse avenues of therapeutic design for multiple diseases and development pathways derived from our unified modular biologic design.
Our solution is an anti-viral, therefore is targeted to infected patients. Vaccines are focused on creating immune response in noninfected population. There is synergy to have both anti-viral and vaccine solutions to combat any outbreak such as COVID. Antivirals keep the virus from spreading and patients from dying. Our anti-viral therapy will always be more quickly adapted than vaccines due to the complex nature of vaccine development and vaccination logistics globally. Therefore, large opportunity exists regardless of success of vaccines.
By the same mechanism we are also to reconfigure our therapeutic to target ‘rogue’ tumor-specific products in cancer cells. In Phase 2, anti-cancer modular designs can also be deployed in conjunction with other modes of anti-cancer treatments, for synergistic action. In this way, can decrease dosage of agents used in combination to increase safety and at the same time increase efficacy, and expand the market for Sanatio